Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

Fig. 3

Change from baseline in brain amyloid pathophysiology. Results as measured by amyloid PET SUVr are shown in a. Outcomes from the qualitative (binary) visual read of the PET scans for conversion of brain amyloid pathology from positive to negative are depicted in b. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (all nominal). For PET analysis, N = 306 at 12 months and N = 288 at 18 months. The PET substudy was optional, so only a portion of the total enrolled subject population opted to participate

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193